Whirly lollipop on orange background.

GenSight (NASDAQ: GNST)  is smaller size biotech deal with Leerick, Evercore and Canaccord on the cover. The 4.6M shares are all primary with a $14 mid-point. It's scheduled for tonight, November 5th. Post-IPO there will be close to 19M shares with a market capitalization of $270M.

This French company has two products for treating eye disease. They target forms of blindness that don't currently have effective treatments. The CEO has quite a bit of experience including the recent success at founding Fovea in 2005 which was sold to Sanofi in 2009. Generally speaking . . .

Want the rest of the article?

Please login or join us as a member to view our complete content!